drugset / Trial / NCT02429193
Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label phase 2 multi-center study of abiraterone and enzalutamide in men with castration-resistant prostate cancer. Sixteen patients will be enrolled over 18 months.
Timeline
- Start
- 2016-03
- Primary completion
- 2019-09-01
- Completion
- 2019-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Prednisone | Other / unclassified | 5 mg | Oral |